AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

NEUROTECH INTERNATIONAL LTD

0.019

0.000

Volume:- -

Turnover:- -

Market Cap:19.94M

PE:-1.59

High:0.019

Open:0.019

Low:0.019

Close:0.019

Loading ...

Overview Company News Filings

Change of Registered Address & Principal Place of Business-NTI.AX

Becoming a substantial holder-NTI.AX

New Scientific Publication of Phase I/II Rett Syndrome Trial-NTI.AX

Neurotech International Appoints Chief Medical Advisor in the US

MT Newswires Live

Neurotech International Says Oral Toxicology Studies of NTI164 Drug Candidate Demonstrate No Safety Concerns

MT Newswires Live

BUZZ-Australia's Neurotech gains as Rett Syndrome drug gets 'orphan' tag from EU

Neurotech's Drug Candidate Receives Orphan Drug Status from European Commission; Shares Rise 3%

MT Newswires Live

Neurotech International Says European Commission Grants NTI164 Orphan Drug Designation

Neurotech International - European Commission Grants Nti164 Orphan Drug Designation for Rett Syndrome

THOMSON REUTERS

Here's Why Neurotech International (ASX:NTI) Must Use Its Cash Wisely

Simply Wall St.

Here's Why We're A Bit Worried About Neurotech International's (ASX:NTI) Cash Burn Situation

Simply Wall St.

BRIEF-Neurotech International Logs HY Loss From Ordinary Activities A$7.445 Mln

BRIEF-Neurotech International Says European Medicines Agency Issued Positive Opinion On Orphan Medicinal Product Designation Application Of NTI164

Neurotech International - Hy Loss From Ordinary Activities a$7.445 Mln

THOMSON REUTERS

Neurotech International - European Medicines Agency Issued Positive Opinion on Orphan Medicinal Product Designation Application of Nti164

THOMSON REUTERS

Neurotech International Signs Cannabis-Based Product Development Deal

MT Newswires Live

BRIEF-Neurotech International Signs Development Agreement For Cannabinoid Therapies

Neurotech International Ltd - Nti Signs Development Agreement for Cannabinoid Therapies

THOMSON REUTERS

Neurotech International - Enters Partnership Agreement With RH Farma Dooel Skopje

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NTI.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NTI.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTI.AU\",,,,,undefined,":{"symbol":"NTI.AU","market":"AU","secType":"STK","nameCN":"NEUROTECH INTERNATIONAL LTD","latestPrice":0.019,"timestamp":1752646320000,"preClose":0.019,"halted":0,"volume":0,"delay":0,"nameEN":"NEUROTECH INTERNATIONAL LTD","floatShares":768083617,"shares":1049621921,"eps":-0.011964,"marketStatus":"Not Yet Opened","change":0,"latestTime":"07-16 16:12:00 AEST","open":0.019,"high":0.019,"low":0.019,"amount":0,"amplitude":0,"askPrice":0.019,"askSize":662513,"bidPrice":0.017,"bidSize":30000,"shortable":3,"etf":0,"ttmEps":-0.011964,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1752710400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.019,"openAndCloseTimeList":[[1752624000000,1752645600000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NTI.AU\",,,,,undefined,":{"symbol":"NTI.AU","floatShares":768083617,"roa":"-129.79%","roe":"-223.80%","lyrEps":-0.005558,"shares":1049621921,"dividePrice":0,"high":0.019,"amplitude":0,"preClose":0.019,"low":0.019,"week52Low":0.015,"pbRate":"3.48","psRate":"247.81","week52High":0.086,"institutionHeld":0,"latestPrice":0.019,"committee":-0.913359,"eps":-0.011964,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.011964,"open":0.019,"prevYearClose":0.055,"prevWeekClose":0.018,"prevMonthClose":0.015,"prevQuarterClose":0.015,"fiveDayClose":0.019,"twentyDayClose":0.017,"sixtyDayClose":0.027},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NTI.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2550161384","title":"Change of Registered Address & Principal Place of Business-NTI.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550161384","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550161384?lang=en_us&edition=fundamental","pubTime":"2025-07-10 14:32","pubTimestamp":1752129131,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250710:nASX71MgMh","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250710:nASX23NyrZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2550395680","title":"Becoming a substantial holder-NTI.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2550395680","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2550395680?lang=en_us&edition=fundamental","pubTime":"2025-07-09 16:58","pubTimestamp":1752051499,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250709:nASX1qPhhV","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250709:nASX8XQrlp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2549374940","title":"New Scientific Publication of Phase I/II Rett Syndrome Trial-NTI.AX","url":"https://stock-news.laohu8.com/highlight/detail?id=2549374940","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2549374940?lang=en_us&edition=fundamental","pubTime":"2025-07-07 07:32","pubTimestamp":1751844770,"startTime":"0","endTime":"0","summary":"https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250706:nASX6nswVk","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250706:nASXbPQzyN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2543660642","title":"Neurotech International Appoints Chief Medical Advisor in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2543660642","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2543660642?lang=en_us&edition=fundamental","pubTime":"2025-06-16 13:03","pubTimestamp":1750050214,"startTime":"0","endTime":"0","summary":"Neurotech International (ASX:NTI) has appointed Bonni Goldstein as Chief Medical Advisor in the US, according to a Monday Australian bourse filing.Goldstein is a physician with more than 25 years of clinical experience, including 17 years focused on cannabinoid-based therapeutics.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","NTI.AU","XAO.AU","XJO.AU","BK7007"],"gpt_icon":0},{"id":"2533372171","title":"Neurotech International Says Oral Toxicology Studies of NTI164 Drug Candidate Demonstrate No Safety Concerns","url":"https://stock-news.laohu8.com/highlight/detail?id=2533372171","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533372171?lang=en_us&edition=fundamental","pubTime":"2025-05-05 14:15","pubTimestamp":1746425751,"startTime":"0","endTime":"0","summary":"Neurotech International  said the 28-day good laboratory practice oral toxicology studies in rats and dogs evaluating its NTI164 drug candidate demonstrated excellent tolerability and no safety concerns, according to a Monday Australian bourse filing.The animals received twice-daily oral dosing across low, mid, and high dose levels, followed by a 14-day recovery period.It said that no test article-related adverse effects were observed across clinical observations, ophthalmic exams, neurological assessments, or clinical pathology.The firm is focused on treating paediatric neurological disorders via the NTI164 broad-spectrum oral cannabinoid drug therapy candidate.Its shares rose 9% on Monday's close.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2523952287","title":"BUZZ-Australia's Neurotech gains as Rett Syndrome drug gets 'orphan' tag from EU","url":"https://stock-news.laohu8.com/highlight/detail?id=2523952287","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523952287?lang=en_us&edition=fundamental","pubTime":"2025-03-31 12:35","pubTimestamp":1743395723,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Neurotech gains as Rett Syndrome drug gets 'orphan' tag from EU   ** Shares of Neurotech International NTI.AX rise 6.5% to A$0.033** Stock set for strongest session since March 18, if current gains hold** European Commission gives \"orphan drug\" designation to biopharmaceutical firm's NTI64 drug aimed at treating Rett Syndrome, a neurodevelopmental disorder that affects motor and communication skills** European Commission grants \"orphan drug\" designation to promote medicine development for rare diseases affecting no more than 5 in 10,000 people in the European Union** Co says \"orphan\" status gives it a range of incentives including 10-year market exclusivity, reduced regulatory fees and access to EU research funding** Stock down 40% YTD, including current session's moves  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nL6N3QE07B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2523956755","title":"Neurotech's Drug Candidate Receives Orphan Drug Status from European Commission; Shares Rise 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2523956755","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523956755?lang=en_us&edition=fundamental","pubTime":"2025-03-31 11:27","pubTimestamp":1743391639,"startTime":"0","endTime":"0","summary":"Neurotech International  has received Orphan Drug Designation from the European Commission for NTI164, its lead drug candidate for Rett Syndrome, a neurodevelopmental disorder, according to a Monday filing with the Australian bourse.The designation grants market exclusivity, reduced regulatory fees, access to research funding, and protocol assistance, the filing said.Shares of the firm rose past 3% in recent Monday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2523378029","title":"Neurotech International Says European Commission Grants NTI164 Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=2523378029","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523378029?lang=en_us&edition=fundamental","pubTime":"2025-03-31 09:51","pubTimestamp":1743385917,"startTime":"0","endTime":"0","summary":"March 31 (Reuters) - Neurotech International Ltd ::*EUROPEAN COMMISSION GRANTS NTI164 ORPHAN DRUG DESIGNATION FOR RETT SYNDROME  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 30-MAR-202522:39:26.03 GMT","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250331:nRSD3rRfpg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2523180982","title":"Neurotech International -  European Commission Grants Nti164 Orphan Drug Designation for Rett Syndrome","url":"https://stock-news.laohu8.com/highlight/detail?id=2523180982","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523180982?lang=en_us&edition=fundamental","pubTime":"2025-03-31 06:40","pubTimestamp":1743374453,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250330:nFWN3QC00I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2518881478","title":"Here's Why Neurotech International (ASX:NTI) Must Use Its Cash Wisely","url":"https://stock-news.laohu8.com/highlight/detail?id=2518881478","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518881478?lang=en_us&edition=fundamental","pubTime":"2025-03-09 07:47","pubTimestamp":1741477643,"startTime":"0","endTime":"0","summary":"We can readily understand why investors are attracted to unprofitable companies. For example, although software-as-a-service business Salesforce.com lost money for years while it grew recurring revenue, if you held shares since 2005, you'd have done very well indeed. Nonetheless, only a fool would ignore the risk that a loss making company burns through its cash too quickly.So, the natural question for Neurotech International  shareholders is whether they should be concerned by its rate of cash burn. For the purposes of this article, cash burn is the annual rate at which an unprofitable company spends cash to fund its growth; its negative free cash flow. The first step is to compare its cash burn with its cash reserves, to give us its 'cash runway'.How Is Neurotech International's Cash Burn Changing Over Time?Since it has a market capitalisation of AU$34m, Neurotech International's AU$9.8m in cash burn equates to about 29% of its m","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/heres-why-neurotech-international-asx-234723303.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2517912667","title":"Here's Why We're A Bit Worried About Neurotech International's (ASX:NTI) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2517912667","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517912667?lang=en_us&edition=fundamental","pubTime":"2025-03-05 13:41","pubTimestamp":1741153274,"startTime":"0","endTime":"0","summary":"Just because a business does not make any money, does not mean that the stock will go down. For example, although...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6021000-choice2-main-header/1585186837163"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/healthcare/asx-nti/neurotech-international-shares/news/heres-why-were-a-bit-worried-about-neurotech-internationals","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2514821051","title":"BRIEF-Neurotech International Logs HY Loss From Ordinary Activities A$7.445 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514821051","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514821051?lang=en_us&edition=fundamental","pubTime":"2025-02-27 16:15","pubTimestamp":1740644120,"startTime":"0","endTime":"0","summary":"BRIEF-Neurotech International Logs HY Loss From Ordinary Activities A$7.445 MlnFeb 27 (Reuters) - Neurotech International Ltd NTI.AX:HY LOSS FROM ORDINARY ACTIVITIES A$7.445 MILLIONFurther company coverage: NTI.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI0UR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2514682114","title":"BRIEF-Neurotech International Says European Medicines Agency Issued Positive Opinion On Orphan Medicinal Product Designation Application Of NTI164","url":"https://stock-news.laohu8.com/highlight/detail?id=2514682114","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514682114?lang=en_us&edition=fundamental","pubTime":"2025-02-27 16:12","pubTimestamp":1740643950,"startTime":"0","endTime":"0","summary":"BRIEF-Neurotech International Says European Medicines Agency Issued Positive Opinion On Orphan Medicinal Product Designation Application Of NTI164Feb 27  - Neurotech International Ltd NTI.AX:EUROPEAN MEDICINES AGENCY ISSUED POSITIVE OPINION ON ORPHAN MEDICINAL PRODUCT DESIGNATION APPLICATION OF NTI164Further company coverage: NTI.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1LP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2514825169","title":"Neurotech International - Hy Loss From Ordinary Activities a$7.445 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514825169","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514825169?lang=en_us&edition=fundamental","pubTime":"2025-02-27 15:42","pubTimestamp":1740642152,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PI0UR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2514819488","title":"Neurotech International - European Medicines Agency Issued Positive Opinion on Orphan Medicinal Product Designation Application of Nti164","url":"https://stock-news.laohu8.com/highlight/detail?id=2514819488","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514819488?lang=en_us&edition=fundamental","pubTime":"2025-02-27 10:00","pubTimestamp":1740621640,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250227:nFWN3PH1LP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2511502435","title":"Neurotech International Signs Cannabis-Based Product Development Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2511502435","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511502435?lang=en_us&edition=fundamental","pubTime":"2025-02-14 07:48","pubTimestamp":1739490498,"startTime":"0","endTime":"0","summary":"Neurotech International  signed an agreement with RH Farma Dooel Skopje, a subsidiary of European Cannabis Company, to develop cannabinoid therapies, according to a Thursday filing with the Australian bourse.The development aims to create a pharmaceutical-grade broad-spectrum cannabinoid drug product for pediatric neurodevelopmental disorders, the filing said.The agreement involves an initial payment of 25,000 euros, with additional services to be provided over a 12-month term, according to the filing.Neurotech International's shares fell past 2% in recent Friday trade.Price : $0.04, Change: $-0.0010, Percent Change: -2.27%","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUD","BK7007","NTI.AU","LU0426412945.USD","LU0345774631.USD","LU0426417589.USD","LU0994945656.USD","LU1043141123.HKD","LU2238339852.HKD","BK4125"],"gpt_icon":0},{"id":"2511559889","title":"BRIEF-Neurotech International Signs Development Agreement For Cannabinoid Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2511559889","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511559889?lang=en_us&edition=fundamental","pubTime":"2025-02-13 09:42","pubTimestamp":1739410942,"startTime":"0","endTime":"0","summary":"BRIEF-Neurotech International Signs Development Agreement For Cannabinoid TherapiesFeb 13  - Neurotech International Ltd NTI.AX:NEUROTECH INTERNATIONAL LTD - NTI SIGNS DEVELOPMENT AGREEMENT FOR CANNABINOID THERAPIESNEUROTECH INTERNATIONAL - ENTERS PARTNERSHIP AGREEMENT WITH RH FARMA DOOEL SKOPJEFurther company coverage: NTI.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250213:nFWN3P321H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NTI.AU","BK7007"],"gpt_icon":0},{"id":"2511531513","title":"Neurotech International Ltd - Nti Signs Development Agreement for Cannabinoid Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2511531513","media":"THOMSON REUTERS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511531513?lang=en_us&edition=fundamental","pubTime":"2025-02-13 06:59","pubTimestamp":1739401171,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P321H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NTI.AU"],"gpt_icon":0},{"id":"2511315155","title":"Neurotech International - Enters Partnership Agreement With RH Farma Dooel Skopje","url":"https://stock-news.laohu8.com/highlight/detail?id=2511315155","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511315155?lang=en_us&edition=fundamental","pubTime":"2025-02-13 06:59","pubTimestamp":1739401171,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nFWN3P321H:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7007","NTI.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":19,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NTI.AU\",params:#limit:5,,,undefined,":[{"date":"2023-10-27","symbol":"NTI.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1698361200000,"name":null,"time":"","dateTimestamp":1698325200000,"actualEps":null},{"date":"2023-07-26","symbol":"NTI.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1690329600000,"name":null,"time":"","dateTimestamp":1690293600000,"actualEps":null},{"market":"AU","date":"2023-04-27","symbol":"NTI.AU","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1682517600000,"reportTimeType":"","actualEps":null},{"date":"2023-01-30","symbol":"NTI.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1675033200000,"name":null,"time":"","dateTimestamp":1674997200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NTI.AU\",market:\"AU\",,,undefined,":[]}}